Thyroid Nodule
Conditions
Keywords
quality of life, anxiety, depression, spiritual health, thermal ablation, microwave ablation, thyroid nodules, papillary thyroid carcinoma
Brief summary
The purpose of this observational research is to evaluate and compare the health-related quality of life and emotional well-being of patients with thyroid nodules before and after treatment. This is a data collection study by allowing investigators to access information generated before and after treatment.
Detailed description
The incidence of thyroid nodules is rising worldwide. Papillary thyroid carcinoma (PTC), the most common type of thyroid cancer, has a favorable prognosis, with a low mortality rate and over 90% 10-year survival rate. Thyroidectomy is often applied to manage thyroid nodules as a traditional method. However, thermal ablation (TA), including microwave ablation (MWA), radiofrequency ablation (RFA), and laser ablation, has emerged as an alternative option for selected patients with thyroid function. TA methods are effective, safe, feasible, and have litter influence on thyroid function. Patients with thyroid nodules frequently exhibit higher levels of emotional stress compared to the general population. Additionally, health-related quality of life (QoL) has become an important endpoint and a strong predictor of survival time in medical and health research, underscoring the importance of treatments that not only prolong life but also preserve or enhance QoL. Considering the long survival time of patients with thyroid noduls and the similar therapeutic outcomes between surgery and MWA , it is crucial to pay more attention on patients' QoL and emotional well-being before and after treatment.
Interventions
PROCEDUREthermal ablation
thermal ablation including microwave ablation, radiofrequency ablation of thyroid nodules
PROCEDUREthyroidectomy
surgical resection of thyroid nodules
Sponsors
Ming-an Yu
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Clinical diagnosis of benign thyroid nodules or papillary thyroid carcinoma ; * underwent microwave ablation or thyroidectomy; * ability to understand and cooperate with the survey
Exclusion criteria
* serious primary diseases in the liver, kidney, hematopoietic, or endocrine systems； * a history of mental illness, personality disorders, cognitive impairments, or organic brain disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Thyroid Cancer-Specific Quality of Life Questionnaire to assess the thyroid-specific quality of life | before treatment and 1month, 6months, and 12 months after treatment | The Thyroid Cancer-Specific Quality of Life Questionnaire (THYCA-QoL), as a methodologically developed questionnaire, was used to assess thyroid-specific symptoms in thyroid cancer survivors. The questionnaire consists of seven symptom scales (neuromuscular, voice, concentration, sympathetic, throat/mouth, psychological and sensory problems) and six single items (problems with scar, felt chilly, tingling hands/feet, gained weight, headache, less interest in sex), with a time frame of the previous week (except for less interest in sex item, which is four weeks), and each item is scored on a four-point response scale ranging from 1, not at all, to 4, very much. Scores were linearly transformed to a 0-100 scale. A higher score on this scale means more symptoms and complaints. |
| the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to assess the general quality of life | before treatment and 1month, 6months, and 12 months after treatment | The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) was adopted as a valid measurement of quality of life for cancer patients. It consists of 5 functional scales , 3 symptom scales, 6 single-item common symptom, and global health status (GHS) subscales. The time frame of the questions is the previous week, and each item is scored on a four-point response scale ranging from 1 to 4, except the global status scale, which is scored on a seven-point modified linear analog scale ranging from 1, very poor to 7, excellent. After linear transformation, all scales and single item measures range in score from 0-100. A higher score on the functional scales and global status scale means a better level of functioning and HRQoL, whereas a a higher score on the symptom scales and single item corresponds to more discomfort and complaints. |
| Hospital Anxiety and Depression Scale to assess the emotional status | before treatment and 1month, 6months, and 12 months after treatment | The Hospital Anxiety and Depression Scale consists of 14 items measuring symptom severity on a scale of 0-3 with subscales for anxiety (HADS\_A) and depression (HADS\_D), and a range of possible scores for each subscale of 0-21. Cut-off scores of 8+ for both subscales demonstrate the optimal balance between sensitivity and specificity for identifying cases of anxiety disorders and depression, with sensitivity and specificity of approximately .8 for both subscales. |
| The functional assessment of chronic illness therapy-spiritual well-being questionnaire to assess spiritual well-being | before treatment and 1month, 6months, and 12 months after treatment | The functional assessment of chronic illness therapy-spiritual well-being scale consists of 12 items formatted in a five-point Likert scale ranging from 0 = not at all to 4 = very much, with the exception of two negatively stated items (4 and 8) coded in a reverse manner. The responses to the self-reported items refer to a 7-day recall period. The scores are added to generate a total score ranging from 0 to 48. With the highest scores representing better spiritual wellbeing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| serum thyroid hormone | before treatment and 1month, 6months, and 12 months after treatment | changes in serum thyroid hormone |
| Percent Volume Changes of Nodules | before treatment and 1month, 6months, and 12 months after treatment | Percent Volume Changes of Nodules: ((Volume (baseline)- Volume (\*m\*))/Volume (baseline))\*100 |
Countries
China
Contacts
Primary Contactming'an yu, MD
Backup Contactyan li
Outcome results
None listed